Pharmacare News Bulletins
Nova Scotia Pharmacare
Pharmacare News Bulletins
The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.
Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.
Latest Issues
August Bulletin Vol. 18–05
New Exception Status Benefits: Ibrance (palbociclib) and Erelzi (etanercept); Criteria Updates: Ciprodex (dexamethasone and ciprofloxacin) and Duloxetine (Cymbalta and generic brands); Move to Full Benefit Status: atomoxetine, buprenorphine/naloxone, capecitabine, clopidogrel, and methadone; Therapeutic Substitution Policy Update; Influenza Vaccine Information
July Bulletin Vol. 18-04
Pre-exposure Prophylaxis for HIV
April Bulletin Vol. 18 – 03
New Exception Status Benefits: Lenvima; Criteria Updates for Hepatitis C Medications: Daklinza, Epclusa, Harvoni, Sovaldi, and Zepatier; New Diabetic Product: Single-Let Lancets
March Bulletin Vol. 18 – 02
Nova Scotia Formulary Updates: Changes to Maximum Reimbursable Prices
January Bulletin Vol. 18 – 01
New Exception Status Benefits – Copaxone (glatiramer acetate), Avonex, Rebif (interferon beta-1a), and Betaseron, Extavia (interferon beta-1b); New Products – Cimzia, Revlimid, Sandoz Amlodipine; New Request for Coverage Form – Oral Diabetes Treatments
Latest Issue
August Bulletin Vol. 18–04
New Exception Status Benefits: Ibrance (palbociclib) and Erelzi (etanercept); Criteria Updates: Ciprodex (dexamethasone and ciprofloxacin) and Duloxetine (Cymbalta and generic brands); Move to Full Benefit Status: atomoxetine, buprenorphine/naloxone, capecitabine, clopidogrel, and methadone.
July Bulletin Vol. 18-03
Pre-exposure Prophylaxis for HIV
April Bulletin Vol. 18-02
New Exception Status Benefits: Lenvima; Criteria Updates for Hepatitis C Medications: Daklinza, Epclusa, Harvoni, Sovaldi, and Zepatier; New Diabetic Product: Single-Let Lancets
January Bulletin Vol. 18 – 01
New Exception Status Benefits – Copaxone (glatiramer acetate), Avonex, Rebif (interferon beta-1a), and Betaseron, Extavia (interferon beta-1b); New Products – Cimzia, Revlimid, Sandoz Amlodipine; New Request for Coverage Form – Oral Diabetes Treatments
Previous Pharmacists' Bulletins
Complete Volume Seventeen 2017 (PDF)
Complete Volume Sixteen 2016 (PDF)
Complete Volume Fifteen 2015 (PDF)
Previous Physicians' Bulletins
Complete Volume Seventeen 2017 (PDF)
Complete Volume Sixteen 2016 (PDF)
Complete Volume Fifteen 2015 (PDF)